Navigation Links
Omeros Appoints David A. Mann to its Board of Directors
Date:8/13/2008

SEATTLE, Aug. 13 /PRNewswire/ -- Omeros Corporation has announced the appointment of David A. Mann to the Company's Board of Directors. Mr. Mann also serves as Chairman of the Board's audit committee.

"Dave's years of executive management experience in finance and operations in the biotechnology sector are an invaluable asset to Omeros," stated Gregory Demopulos, M.D., Chairman and CEO of Omeros. "He is an important addition to our Board, and I expect that he will play an integral role as we prepare for product commercialization."

"Dr. Demopulos and his team have done an excellent job in advancing their PharmacoSurgery platform, and I am pleased to be working with them," commented David Mann. "With a deep pipeline focused on inflammation and CNS, Omeros represents an exciting opportunity."

Mr. Mann brings with him over 20 years of executive management, finance and operations experience in the biotechnology industry. He was executive vice president and chief financial officer at Immunex prior to and during its acquisition by Amgen, and held senior financial positions at the Fred Hutchinson Cancer Research Center. Mr. Mann serves on the Board of Directors of Trubion Pharmaceuticals, and is on the advisory board of the Western Washington University College of Business and Economics and the Western Washington University Foundation Board. He is a former Certified Public Accountant, and earned his M.B.A. from the University of Washington and a B.A. from Western Washington University.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. For more information on Omeros, visit the Company's Web site at http://www.omeros.com.


'/>"/>
SOURCE Omeros Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
2. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
3. SpineMark Appoints Dr. Rudolf Bertagnoli Chairman of International Medical Advisory Board
4. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
5. SAFC Appoints New Vice President of Quality and Regulatory Affairs
6. Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
7. ARCA biopharma Appoints James Carr as Vice President of Marketing
8. China Biologic Products Establishes Audit Committee and Appoints Three New Independent Directors to Board of Directors
9. Health Monitoring Systems Appoints Karen S. Dockrell As VP, Sales
10. Human Genome Sciences Appoints David P. Southwell to its Board of Directors
11. Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , ... May 04, 2016 , ... PBI-Gordon Corporation is ... Agricultural Sales. , Doug began his career at PBI-Gordon in February 1988, after ... a wide variety of roles, ranging from customer service to national product manager, to ...
(Date:5/3/2016)... ... 03, 2016 , ... Morf Media Inc ., developer ... on mobile devices, today released a new interactive Food and Drug Administration ... course is essential for owners or operators of places of business that are ...
(Date:5/3/2016)... CO (PRWEB) , ... May 03, 2016 , ... ... , announced the addition of Dr. Nancy Gillett to its Board of Directors. ... position, she served as Corporate Executive Vice President and Chief Scientific Officer. A ...
(Date:5/3/2016)... LONDON , May 3, 2016 ... Report Assessing Developers and Producers of Those Competitor Biologics  ... Guide to Companies, Activities and Prospects ,  ... drug companies? And what are their sales potentials? ... There you see results, trends, opportunities and revenue forecasting. ...
Breaking Biology Technology:
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):